IDEXX Laboratories (IDXX) 10-Q 25 Apr 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 16, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'IDEXX LABORATORIES INC /DE	'
Entity Central Index Key	'0000874716	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Common Stock, Shares Outstanding	'	51,304,867

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$286,203	$279,058
Accounts receivable, net of reserves of $3,784 in 2014 and $3,533 in 2013	179,919	158,038
Inventories	141,134	133,427
Deferred income tax assets	32,005	33,226
Other current assets	43,905	48,957
Total current assets	683,166	652,706
Long-Term Assets:	'	'
Property and equipment, net	282,226	281,214
Goodwill	180,466	180,521
Intangible assets, net	57,281	58,844
Other long-term assets, net	59,185	57,231
Total long-term assets	579,158	577,810
TOTAL ASSETS	1,262,324	1,230,516
Current Liabilities:	'	'
Accounts payable	42,794	29,941
Accrued liabilities	134,519	148,919
Line of credit	315,000	277,000
Current portion of long-term debt	1,050	1,035
Current portion of deferred revenue	23,810	21,458
Total current liabilities	517,173	478,353
Long-Term Liabilities:	'	'
Deferred income tax liabilities	31,785	33,948
Long-term debt, net of current portion	150,090	150,359
Long-term deferred revenue, net of current portion	19,264	18,427
Other long-term liabilities	31,760	31,215
Total long-term liabilities	232,899	233,949
Total liabilities	750,072	712,302
Commitments and Contingencies (Note 12)	'	'
Stockholders' Equity:	'	'
Common stock, $0.10 par value per share: Authorized: 120,000 shares; Issued: 101,554 and 101,188 shares in 2014 and 2013, respectively	10,155	10,119
Additional paid-in capital	847,138	825,320
Deferred stock units: Outstanding: 122 units in 2014 and 2013	5,104	5,110
Retained earnings	1,539,978	1,493,393
Accumulated other comprehensive income	14,445	13,622
Treasury stock, at cost: 50,264 and 49,649 shares in 2014 and 2013, respectively	-1,904,604	-1,829,378
Total IDEXX Laboratories, Inc. stockholders' equity	512,216	518,186
Noncontrolling interest	36	28
Total stockholders' equity	512,252	518,214
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$1,262,324	$1,230,516

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets [Abstract]	'	'
Accounts receivable, reserves	$3,784	$3,533
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	101,554,000	101,188,000
Deferred stock units, outstanding	122,000	122,000
Treasury stock, shares	50,264,000	49,649,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Product revenue	$219,392	$205,768
Service revenue	140,811	126,338
Total revenue	360,203	332,106
Cost of Revenue:	'	'
Cost of product revenue	78,042	74,150
Cost of service revenue	80,064	73,982
Total cost of revenue	158,106	148,132
Gross profit	202,097	183,974
Expenses:	'	'
Sales and marketing	67,848	59,397
General and administrative	41,089	41,631
Research and development	23,114	21,758
Income from operations	70,046	61,188
Interest expense	-2,774	-835
Interest income	471	444
Income before provision for income taxes	67,743	60,797
Provision for income taxes	21,150	15,930
Net income	46,593	44,867
Less: Net income attributable to noncontrolling interest	8	7
Net income attributable to IDEXX Laboratories, Inc. stockholders	$46,585	$44,860
Earnings per Share:	'	'
Basic	$0.90	$0.82
Diluted	$0.89	$0.81
Weighted Average Shares Outstanding:	'	'
Basic	51,617	54,588
Diluted	52,338	55,490

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Comprehensive Income [Abstract]	'	'
Net income	$46,593	$44,867
Other comprehensive income (loss), net of tax:	'	'
Foreign currency translation adjustments	1,279	-8,447
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($32) in 2014 and $42 in 2013	-54	72
Unrealized gain (loss) on derivative instruments:	'	'
Unrealized (loss) gain, net of tax (benefit) expense of ($123) in 2014 and $1,699 in 2013	-253	4,118
Less: reclassification adjustment for gains included in net income, net of tax (expense) benefit of ($47) in 2014 and $8 in 2013	-149	-10
Unrealized (loss) gain on derivative instruments	-402	4,108
Other comprehensive income (loss), net of tax	823	-4,267
Comprehensive income	47,416	40,600
Less: comprehensive income attributable to noncontrolling interest	8	7
Comprehensive income attributable to IDEXX Laboratories, Inc.	$47,408	$40,593

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Comprehensive Income [Abstract]	'	'
Unrealized (loss) gain on investments, tax (benefit) expense	($32)	$42
Unrealized (loss) gain, tax (benefit) expense	-123	1,699
Reclassification adjustment for gains included in net income, tax (expense) benefit	($47)	$8

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows from Operating Activities:	'	'
Net income	$46,593,000	$44,867,000
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	13,394,000	13,513,000
(Gain) loss on disposal of property and equipment	-18,000	27,000
(Decrease) increase in deferred compensation liability	-86,000	114,000
Provision for uncollectible accounts	451,000	644,000
(Benefit of) provision for deferred income taxes	-835,000	1,169,000
Share-based compensation expense	4,108,000	3,949,000
Tax benefit from share-based compensation arrangements	-6,747,000	-5,310,000
Changes in assets and liabilities:	'	'
Accounts receivable	-21,707,000	-23,722,000
Inventories	2,200,000	-10,717,000
Other assets	1,312,000	6,301,000
Accounts payable	1,857,000	5,567,000
Accrued liabilities	-10,231,000	-16,216,000
Deferred revenue	3,227,000	869,000
Net cash provided by operating activities	33,518,000	21,055,000
Cash Flows from Investing Activities:	'	'
Purchases of property and equipment	-11,298,000	-20,132,000
Proceeds from disposition of pharmaceutical product lines	'	3,500,000
Acquisitions of intangible assets	-175,000	-659,000
Acquisition of businesses, net of cash acquired	-1,161,000	'
Net cash used by investing activities	-12,634,000	-17,291,000
Cash Flows from Financing Activities:	'	'
Borrowings on revolving credit facilities, net	38,000,000	48,000,000
Debt issue costs	-139,000	'
Payment of notes payable	-253,000	-238,000
Repurchases of common stock	-70,279,000	-63,778,000
Proceeds from exercises of stock options and employee stock purchase plans	10,964,000	12,958,000
Tax benefit from share-based compensation arrangements	6,747,000	5,310,000
Net cash (used) provided by financing activities	-14,960,000	2,252,000
Net effect of changes in exchange rates on cash	1,221,000	-1,638,000
Net increase in cash and cash equivalents	7,145,000	4,378,000
Cash and cash equivalents at beginning of period	279,058,000	279,058,000
Cash and cash equivalents at end of period	286,203,000	228,364,000
Supplemental Disclosure of Non-Cash Information:	'	'
Market value of common shares received from employees in connection with share-based compensation - see Note 18	$5,000,000	$4,100,000

Basis_Of_Presentation_And_Prin

Basis Of Presentation And Principles Of Consolidation	3 Months Ended
	Mar. 31, 2014
Basis Of Presentation And Principles Of Consolidation [Abstract]	'
Basis Of Presentation And Principles Of Consolidation	'
	NOTE 1.      BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION
	The accompanying condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to "IDEXX," the "Company," "we," "our" or "us" refer to IDEXX Laboratories, Inc. and its subsidiaries.
	The accompanying condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
	The accompanying condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2013 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 and our Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Annual Report”) filed with the Securities and Exchange Commission (“SEC”).
	Reclassifications and Revisions
	Certain prior year amounts have been reclassified to conform with the current year presentation. Reclassifications had no material impact on previously reported results of operations, financial position or cash flows.
	Revisions were made on the condensed consolidated statement of cash flows for the three months ended March 31, 2013 to correctly reflect non-cash investing activities embedded in accounts payable, accrued liabilities and inventory on the condensed consolidated balance sheet at March 31, 2013. These revisions increased the operating cash flows related to the change in accounts payable, accrued liabilities and inventory for the three months ended March 31, 2013 by $0.4 million from the amounts previously reported, and decreased investing cash flows related to purchases of property and equipment by the same amount. The revisions to the condensed consolidated statements of cash flows noted above represent an error that is not deemed to be material, individually or in the aggregate, to the prior period  condensed consolidated financial statements.

Accounting_Policies

Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Note 2.      ACCOUNTING POLICIES
	The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2014 are consistent with those discussed in Note 2 to the consolidated financial statements in our 2013 Annual Report.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation	'
	NOTE 3.      SHARE-BASED COMPENSATION
	The fair value of options, restricted stock units, deferred stock units and employee stock purchase rights awarded during the three months ended March 31, 2014 and 2013 totaled $20.3 million and $16.6 million, respectively. The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding at March 31, 2014 was $49.1 million, which will be recognized over a weighted average period of approximately 2.3 years.
	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards. The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:
		For the Three Months Ended March 31,
			2014			2013
	Expected stock price volatility		28	%		33	%
	Expected term, in years1		5.7			4.6
	Risk-free interest rate		1.5	%		0.9	%
	Weighted average fair value of options granted	$	35.94		$	26.58
	1 Options granted during the three months ended March 31, 2014 and 2013 have a contractual term of ten and seven years, respectively.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	Note 4.      Inventories
	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. The components of inventories were as follows (in thousands):
		March 31,		December 31,
			2014		2013
	Raw materials	$	23,498	$	23,766
	Work-in-process		16,120		14,359
	Finished goods		101,516		95,302
		$	141,134	$	133,427

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets [Abstract]	'
Goodwill and Intangible Assets, Net	'
	Note 5.       Goodwill and Intangible Assets, NET
	The decrease in goodwill during the three months ended March 31, 2014 resulted from changes in foreign currency exchange rates. The decrease in intangible assets other than goodwill during the three months ended March 31, 2014 resulted primarily from the continued amortization of our intangible assets, partly offset by the impact of the acquisition of an immaterial business and certain intangible assets.

Other_Noncurrent_Assets

Other Noncurrent Assets	3 Months Ended
	Mar. 31, 2014
Other Noncurrent Assets [Abstract]	'
Other Noncurrent Assets	'
	NOTE 6.      Other NONCURRENT ASSETS
	Other noncurrent assets consisted of the following (in thousands):
		March 31,		December 31,
			2014		2013
	Investment in long-term product supply arrangements	$	12,577	$	13,075
	Customer acquisition costs, net		20,781		21,199
	Other assets		25,827		22,957
		$	59,185	$	57,231

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	Note 7.      Accrued liabilities
	Accrued liabilities consisted of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Accrued expenses	$	44,567	$	44,274
	Accrued employee compensation and related expenses		48,105		62,474
	Accrued taxes		15,386		16,508
	Accrued customer programs		26,461		25,663
		$	134,519	$	148,919

Repurchases_Of_Common_Stock

Repurchases Of Common Stock	3 Months Ended
	Mar. 31, 2014
Repurchases Of Common Stock [Abstract]	'
Repurchases Of Common Stock	'
	Note 8.      Repurchases of common STOCK
	The following is a summary of our open market common stock repurchases for the three months ended March 31, 2014 and 2013 (in thousands, except per share amounts):
		For the Three Months Ended March 31,
		2014		2013
	Shares repurchased		576		687
	Total cost of shares repurchased	$	70,279	$	63,778
	Average cost per share	$	122.04	$	92.82
	We primarily acquire shares by means of repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. We acquired 40,537 shares having a total cost of $5.0 million in connection with such employee surrenders during the three months ended March 31, 2014 compared to 45,181 shares having a total cost of $4.1 million during the three months ended March 31, 2013.
	We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury stock issued during both the three months ended March 31, 2014 and 2013 was not material.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 9.      Income Taxes
	Our effective income tax rate was 31.2% and 26.2% for the three months ended March 31, 2014 and 2013, respectively. The increase in our effective rate for the three months ended March 31, 2014 as compared to the same period of the prior year was primarily related to the U.S. research and development (R&D) tax credit.  During the quarter ended March 31, 2013, legislation in the U.S. retroactively allowed the R&D tax credit for all of 2012 and extended the credit through the year ended December 31, 2013. Because this legislation was enacted during the quarter ended March 31, 2013, the full benefit of the credit related to the prior years’ activities was recognized within that quarter, lowering our effective tax rate significantly in that period. As of January 1, 2014, the R&D tax credit again expired, increasing our effective tax rate in the period ended March 31, 2014.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income	'
	Note 10.    ACCUMULATED OTHER Comprehensive Income
	The changes in accumulated other comprehensive income, net of tax, for the three months ended March 31, 2014 consisted of the following (in thousands):
	For the Three Months Ended March 31, 2014		Unrealized Gain on Investments, Net of Tax			Unrealized Loss on Derivative Instruments, Net of Tax		Cumulative Translation Adjustment		Total
	Balance as of December 31, 2013	$	108		$	-179	$	13,693	$	13,622
	Other comprehensive (loss) income before reclassifications		-54			-253		1,279		972
	Gains reclassified from accumulated other comprehensive income		-			-149		-		-149
	Balance as of March 31, 2014	$	54		$	-581	$	14,972	$	14,445
	The following is a summary of reclassifications out of accumulated other comprehensive income for the three months ended March 31, 2014 and 2013 (in thousands):
	Details about Accumulated Other Comprehensive Income Components	Affected Line Item in the Statement Where Net Income is Presented		Amounts Reclassified from Accumulated Other Comprehensive Income For the Three Months Ended March 31,
				2014		2013
	Gains (losses) on derivative instruments included in net income:
	Foreign currency exchange contracts	Cost of revenue		458		109
	Interest rate swaps	Interest expense		-262		-107
		Total gains before tax		196		2
		Tax expense (benefit)		47		-8
		Gains, net of tax		149		10

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 11.    Earnings per Share
	Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 to the consolidated financial statements in our 2013 Annual Report for additional information regarding deferred stock units.
	The following is a reconciliation of shares outstanding for basic and diluted earnings per share for the three months ended March 31, 2014 and 2013 (in thousands):
		For the Three Months Ended March 31,
		2014	2013
	Shares outstanding for basic earnings per share:	51,617	54,588
	Shares outstanding for diluted earnings per share:
	Shares outstanding for basic earnings per share	51,617	54,588
	Dilutive effect of share-based payment awards	721	902
		52,338	55,490
	Certain options to acquire shares and restricted stock units have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options and restricted stock units for the three months ended March 31, 2014 and 2013 (in thousands):
		For the Three Months Ended March 31,
		2014	2013
	Weighted average number of shares underlying anti-dilutive options	217	441
	Weighted average number of shares underlying anti-dilutive restricted stock units	41	-

Commitments_Contingencies_And_

Commitments, Contingencies And Guarantees	3 Months Ended
	Mar. 31, 2014
Commitments, Contingencies And Guarantees [Abstract]	'
Commitments, Contingencies And Guarantees	'
	Note 12.    Commitments, Contingencies and Guarantees
	Significant commitments, contingencies and guarantees at March 31, 2014 are consistent with those discussed in Note 14 to the consolidated financial statements in our 2013 Annual Report.

Segment_Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting	'
	Note 13.     Segment Reporting
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic tests for livestock and poultry health and to ensure the quality and safety of milk and food, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment comprises products for the human point-of-care medical diagnostics market (“OPTI Medical”), which is combined and presented with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.
	Items that are not allocated to our operating segments are as follows: a portion of corporate support function and personnel-related expenses; certain manufacturing costs; corporate research and development expenses that do not align with one of our existing business or service categories; the difference between estimated and actual share-based compensation expense; and certain foreign currency exchange gains and losses. These amounts are shown under the caption “Unallocated Amounts.”
	We estimate our share-based compensation expense, corporate support function expenses and certain personnel-related costs and allocate the estimated expenses to the operating segments. This allocation differs from actual expense and consequently yields a difference that is reported under the caption “Unallocated Amounts.”
	With respect to manufacturing costs, the costs reported in our operating segments include our standard cost for products sold and any variances from standard cost for products purchased or manufactured within the period. We capitalize these variances for inventory on hand at the end of the period to record inventory in accordance with U.S. GAAP. We then record these variances as cost of product revenue as that inventory is sold. The impact to cost of product revenue resulting from this variance capitalization and subsequent recognition is reported within the caption “Unallocated Amounts.”
	Additionally, in certain geographies where we maintain inventories in currencies other than the U.S. dollar, the product costs reported in our operating segments include our standard cost for products sold, which is stated at the budgeted currency exchange rate from the beginning of the fiscal year. In these geographies, the variances from standard cost for products sold related to changes in currency exchange rates are reported within the caption “Unallocated Amounts.”
	The following is a summary of segment performance for the three months ended March 31, 2014 and 2013 (in thousands):
		For the Three Months Ended March 31,
		CAG		Water		LPD		Other		Unallocated Amounts		Consolidated Total
	2014
	Revenue	$	301,588	$	21,421	$	31,351	$	5,843	$	-	$	360,203
	Income (loss) from operations	$	55,864	$	8,116	$	6,460	$	589	$	-983	$	70,046
	Interest expense, net												-2,303
	Income before provision for income taxes												67,743
	Provision for income taxes												21,150
	Net income												46,593
	Less: Net income attributable to noncontrolling interest												8
	Net income attributable to IDEXX Laboratories, Inc. stockholders											$	46,585
	2013
	Revenue	$	276,941	$	20,666	$	28,039	$	6,460	$	-	$	332,106
	Income (loss) from operations	$	51,309	$	8,355	$	4,836	$	435	$	-3,747	$	61,188
	Interest expense, net												-391
	Income before provision for income taxes												60,797
	Provision for income taxes												15,930
	Net income												44,867
	Less: Net income attributable to noncontrolling interest												7
	Net income attributable to IDEXX Laboratories, Inc. stockholders											$	44,860
	The following is a summary of revenue by product and service category for the three months ended March 31, 2014 and 2013  (in thousands):
				For the Three Months Ended March 31,
					2014		2013
	CAG segment revenue:
	CAG Diagnostics recurring revenue:			$	258,763	$	239,568
	IDEXX VetLab® consumables				84,321		75,783
	VetLab service and accessories				13,093		12,053
	Rapid assay products				43,059		44,083
	Reference laboratory diagnostic and consulting services				118,290		107,649
	CAG Diagnostics capital - instruments				18,565		15,835
	Customer information management and digital imaging systems				24,260		21,538
	CAG segment revenue				301,588		276,941
	Water segment revenue				21,421		20,666
	LPD segment revenue				31,351		28,039
	Other segment revenue				5,843		6,460
	Total revenue			$	360,203	$	332,106

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	Note 14.     FAIR VALUE MEASUREMENTS
	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.
	The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows:
	Level 1	Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2014.
	Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk.
	The amount outstanding under our unsecured revolving credit facility (“Credit Facility”), notes receivable and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility, notes receivable and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using level 2 inputs, while our notes receivable, representing a strategic investment in a privately held company with a carrying value of $5.2 million as of March 31, 2014,  are valued using level 3 inputs. The results of these calculations yield fair values that approximate carrying values.
	The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis at March 31, 2014 and at December 31, 2013 by level within the fair value hierarchy (in thousands):
			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs		Balance at
	As of March 31, 2014		(Level 1)		(Level 2)		(Level 3)		31-Mar-14
	Assets
	Money market funds(1)		$	173,116	$	-	$	-	$	173,116
	Equity mutual funds(2)			2,765		-		-		2,765
	Foreign currency exchange contracts(3)			-		3,014		-		3,014
	Liabilities
	Foreign currency exchange contracts(3)			-		2,576		-		2,576
	Deferred compensation(4)			2,765		-		-		2,765
	Interest rate swaps(5)			-		1,637		-		1,637
			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs		Balance at
	As of December 31, 2013		(Level 1)		(Level 2)		(Level 3)		31-Dec-13
	Assets
	Money market funds(1)		$	153,109	$	-	$	-	$	153,109
	Equity mutual funds(2)			2,847		-		-		2,847
	Foreign currency exchange contracts(3)			-		4,044		-		4,044
	Liabilities
	Foreign currency exchange contracts(3)			-		3,096		-		3,096
	Deferred compensation(4)			2,847		-		-		2,847
	Interest rate swaps(5)			-		1,821		-		1,821
	_____________
		-1		Money market funds are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of March 31, 2014 and December 31, 2013 consisted of demand deposits.
		-2		Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability.
		-3		Foreign currency exchange contracts are included within other current assets; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.
		-4		A deferred compensation plan assumed as part of a previous business combination is included within other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above.
		-5		Interest rate swaps are included within accrued liabilities.
	The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging [Abstract]	'
Derivative Instruments And Hedging	'
	Note 15.    Derivative Instruments and Hedging
	Disclosure within this footnote is presented to provide transparency about how and why we use derivative instruments, how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows.
	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using derivative instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into foreign currency exchange contracts to minimize the impact of foreign currency fluctuations associated with specific, significant transactions. We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with our variable-rate Credit Facility.
	The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in Euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc.  We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with large multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management.
	We recognize all derivative instruments, including our foreign currency exchange contracts and interest rate swap agreements, on the balance sheet at fair value at the balance sheet date. Derivative instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.  If a derivative instrument qualifies for hedge accounting, changes in the fair value of the derivative instrument from the effective portion of the hedge are deferred in accumulated other comprehensive income (“AOCI”), net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedge instrument is not effective in achieving offsetting changes in fair value. We de-designate derivative instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 10 for further information regarding the effect of derivative instruments designated as cash flow hedges on the condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013.
	We enter into master netting arrangements with the counterparties to our derivative transactions which permit outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral.  We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged.
	Cash Flow Hedges
	We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.
	We did not de-designate any instruments from hedge accounting treatment during the three months ended March 31, 2014 or 2013. Gains or losses related to hedge ineffectiveness recognized in earnings during the three months ended March 31, 2014 and 2013 were not material.  At March 31, 2014, the estimated amount of net losses, net of income tax benefit, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $0.6 million if exchange and interest rates do not fluctuate from the levels at March 31, 2014.
	We enter into foreign currency exchange contracts for amounts that are less than the full value of forecasted intercompany inventory purchases and sales. Our hedging strategy related to intercompany inventory purchases and sales is to employ the full amount of our hedges for the succeeding year at the conclusion of our budgeting process for that year. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $179.0 million and $168.3 million at March 31, 2014 and December 31, 2013, respectively.
	We have entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.36% plus the range of applicable interest rates (“Credit Spread”) through June 30, 2016. Beginning on March 28, 2013, the variable interest rate associated with an additional $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.64% plus the Credit Spread through June 30, 2016.
	The fair values of derivative instruments and their respective classification on the condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands):
			Asset Derivatives
			March 31,				December 31,
				2014			2013
	Derivatives designated as hedging instruments	Balance Sheet Classification
	Foreign currency exchange contracts	Other current assets	$	3,003		$	4,044
	Foreign currency exchange contracts	Other long-term assets, net		11			-
	Total derivative instruments presented on the balance sheet			3,014			4,044
	Gross amounts subject to master netting arrangements not offset on the balance sheet			2,561			2,965
	Net amount		$	453		$	1,079
			Liability Derivatives
			March 31,				December 31,
				2014			2013
	Derivatives designated as hedging instruments	Balance Sheet Classification
	Foreign currency exchange contracts	Accrued liabilities	$	2,571		$	3,096
	Foreign currency exchange contracts	Other long-term liabilities		5			-
	Interest rate swaps	Accrued liabilities		1,637			1,821
	Total derivative instruments presented on the balance sheet			4,213			4,917
	Gross amounts subject to master netting arrangements not offset on the balance sheet			2,561			2,965
	Net amount		$	1,652		$	1,952
	The effect of derivative instruments designated as cash flow hedges on the condensed consolidated balance sheets consisted of the following (in thousands):
					(Loss) Gain Recognized in OCI on Derivative Instruments (Effective Portion)
					For the Three Months Ended March 31,
	Derivative instruments					2014			2013
	Foreign currency exchange contracts, net of tax				$	-517		$	4,061
	Interest rate swaps, net of tax					115			47
	Total derivative instruments, net of tax				$	-402		$	4,108

ShareBased_Compensation_Policy

Share-Based Compensation (Policy)	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation Policy	'
	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

Inventories_Policy

Inventories (Policy)	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories Policy	'
	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges.

Earnings_Per_Share_Policy

Earnings Per Share (Policy)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share Policy	'
	Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.

Fair_Value_Measurements_Policy

Fair Value Measurements (Policy)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements Policy	'
	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.
	The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows:
	Level 1	Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2014.
	Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk.
	The amount outstanding under our unsecured revolving credit facility (“Credit Facility”), notes receivable and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility, notes receivable and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using level 2 inputs, while our notes receivable, representing a strategic investment in a privately held company with a carrying value of $5.2 million as of March 31, 2014,  are valued using level 3 inputs. The results of these calculations yield fair values that approximate carrying values.

Derivative_Instruments_And_Hed1

Derivative Instruments And Hedging (Policy)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging [Abstract]	'
Derivatives Policy	'
	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using derivative instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into foreign currency exchange contracts to minimize the impact of foreign currency fluctuations associated with specific, significant transactions. We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with our variable-rate Credit Facility.
	The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in Euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc.  We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with large multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management.
	We recognize all derivative instruments, including our foreign currency exchange contracts and interest rate swap agreements, on the balance sheet at fair value at the balance sheet date. Derivative instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.  If a derivative instrument qualifies for hedge accounting, changes in the fair value of the derivative instrument from the effective portion of the hedge are deferred in accumulated other comprehensive income (“AOCI”), net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedge instrument is not effective in achieving offsetting changes in fair value. We de-designate derivative instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 10 for further information regarding the effect of derivative instruments designated as cash flow hedges on the condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013.
	We enter into master netting arrangements with the counterparties to our derivative transactions which permit outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral.  We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged.
	Cash Flow Hedges
	We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	'
		For the Three Months Ended March 31,
			2014			2013
	Expected stock price volatility		28	%		33	%
	Expected term, in years1		5.7			4.6
	Risk-free interest rate		1.5	%		0.9	%
	Weighted average fair value of options granted	$	35.94		$	26.58

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Schedule Of Components Of Inventories	'
		March 31,		December 31,
			2014		2013
	Raw materials	$	23,498	$	23,766
	Work-in-process		16,120		14,359
	Finished goods		101,516		95,302
		$	141,134	$	133,427

Other_Noncurrent_Assets_Tables

Other Noncurrent Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Other Noncurrent Assets [Abstract]	'
Schedule Of Other Noncurrent Assets	'
		March 31,		December 31,
			2014		2013
	Investment in long-term product supply arrangements	$	12,577	$	13,075
	Customer acquisition costs, net		20,781		21,199
	Other assets		25,827		22,957
		$	59,185	$	57,231

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Schedule Of Accrued Liabilities	'
		March 31,		December 31,
		2014		2013
	Accrued expenses	$	44,567	$	44,274
	Accrued employee compensation and related expenses		48,105		62,474
	Accrued taxes		15,386		16,508
	Accrued customer programs		26,461		25,663
		$	134,519	$	148,919

Repurchases_Of_Common_Stock_Ta

Repurchases Of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2014
Repurchases Of Common Stock [Abstract]	'
Schedule Of Common Stock Repurchases	'
		For the Three Months Ended March 31,
		2014		2013
	Shares repurchased		576		687
	Total cost of shares repurchased	$	70,279	$	63,778
	Average cost per share	$	122.04	$	92.82

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Schedule Of Accumulated Other Comprehensive Income	'
	For the Three Months Ended March 31, 2014		Unrealized Gain on Investments, Net of Tax			Unrealized Loss on Derivative Instruments, Net of Tax		Cumulative Translation Adjustment		Total
	Balance as of December 31, 2013	$	108		$	-179	$	13,693	$	13,622
	Other comprehensive (loss) income before reclassifications		-54			-253		1,279		972
	Gains reclassified from accumulated other comprehensive income		-			-149		-		-149
	Balance as of March 31, 2014	$	54		$	-581	$	14,972	$	14,445
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
	Details about Accumulated Other Comprehensive Income Components	Affected Line Item in the Statement Where Net Income is Presented		Amounts Reclassified from Accumulated Other Comprehensive Income For the Three Months Ended March 31,
				2014		2013
	Gains (losses) on derivative instruments included in net income:
	Foreign currency exchange contracts	Cost of revenue		458		109
	Interest rate swaps	Interest expense		-262		-107
		Total gains before tax		196		2
		Tax expense (benefit)		47		-8
		Gains, net of tax		149		10

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	'
		For the Three Months Ended March 31,
		2014	2013
	Shares outstanding for basic earnings per share:	51,617	54,588
	Shares outstanding for diluted earnings per share:
	Shares outstanding for basic earnings per share	51,617	54,588
	Dilutive effect of share-based payment awards	721	902
		52,338	55,490
Schedule Of Number Of Anti-Dilutive Stock Options and Restricted Stock Units	'
		For the Three Months Ended March 31,
		2014	2013
	Weighted average number of shares underlying anti-dilutive options	217	441
	Weighted average number of shares underlying anti-dilutive restricted stock units	41	-

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Summary Of Revenue By Product And Service Category	'
		For the Three Months Ended March 31,
			2014		2013
	CAG segment revenue:
	CAG Diagnostics recurring revenue:	$	258,763	$	239,568
	IDEXX VetLab® consumables		84,321		75,783
	VetLab service and accessories		13,093		12,053
	Rapid assay products		43,059		44,083
	Reference laboratory diagnostic and consulting services		118,290		107,649
	CAG Diagnostics capital - instruments		18,565		15,835
	Customer information management and digital imaging systems		24,260		21,538
	CAG segment revenue		301,588		276,941
	Water segment revenue		21,421		20,666
	LPD segment revenue		31,351		28,039
	Other segment revenue		5,843		6,460
	Total revenue	$	360,203	$	332,106

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	'
			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs		Balance at
	As of March 31, 2014		(Level 1)		(Level 2)		(Level 3)		31-Mar-14
	Assets
	Money market funds(1)		$	173,116	$	-	$	-	$	173,116
	Equity mutual funds(2)			2,765		-		-		2,765
	Foreign currency exchange contracts(3)			-		3,014		-		3,014
	Liabilities
	Foreign currency exchange contracts(3)			-		2,576		-		2,576
	Deferred compensation(4)			2,765		-		-		2,765
	Interest rate swaps(5)			-		1,637		-		1,637
			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs		Balance at
	As of December 31, 2013		(Level 1)		(Level 2)		(Level 3)		31-Dec-13
	Assets
	Money market funds(1)		$	153,109	$	-	$	-	$	153,109
	Equity mutual funds(2)			2,847		-		-		2,847
	Foreign currency exchange contracts(3)			-		4,044		-		4,044
	Liabilities
	Foreign currency exchange contracts(3)			-		3,096		-		3,096
	Deferred compensation(4)			2,847		-		-		2,847
	Interest rate swaps(5)			-		1,821		-		1,821
	_____________
		-1		Money market funds are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of March 31, 2014 and December 31, 2013 consisted of demand deposits.
		-2		Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability.
		-3		Foreign currency exchange contracts are included within other current assets; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.
		-4		A deferred compensation plan assumed as part of a previous business combination is included within other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above.
		-5		Interest rate swaps are included within accrued liabilities.

Derivative_Instruments_And_Hed2

Derivative Instruments And Hedging (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative [Line Items]	'
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	'
					(Loss) Gain Recognized in OCI on Derivative Instruments (Effective Portion)
					For the Three Months Ended March 31,
	Derivative instruments					2014			2013
	Foreign currency exchange contracts, net of tax				$	-517		$	4,061
	Interest rate swaps, net of tax					115			47
	Total derivative instruments, net of tax				$	-402		$	4,108
Assets [Member]	'
Derivative [Line Items]	'
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	'
			Asset Derivatives
			March 31,				December 31,
				2014			2013
	Derivatives designated as hedging instruments	Balance Sheet Classification
	Foreign currency exchange contracts	Other current assets	$	3,003		$	4,044
	Foreign currency exchange contracts	Other long-term assets, net		11			-
	Total derivative instruments presented on the balance sheet			3,014			4,044
	Gross amounts subject to master netting arrangements not offset on the balance sheet			2,561			2,965
	Net amount		$	453		$	1,079
Liabilities [Member]	'
Derivative [Line Items]	'
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	'
			Liability Derivatives
			March 31,				December 31,
				2014			2013
	Derivatives designated as hedging instruments	Balance Sheet Classification
	Foreign currency exchange contracts	Accrued liabilities	$	2,571		$	3,096
	Foreign currency exchange contracts	Other long-term liabilities		5			-
	Interest rate swaps	Accrued liabilities		1,637			1,821
	Total derivative instruments presented on the balance sheet			4,213			4,917
	Gross amounts subject to master netting arrangements not offset on the balance sheet			2,561			2,965
	Net amount		$	1,652		$	1,952

Nature_Of_Business_Basis_Of_Pr

Nature Of Business, Basis Of Presentation And Principles Of Consolidation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Basis Of Presentation And Principles Of Consolidation [Abstract]	'
Revision to correctly reflect non-cash investing activities	$0.40

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-Based Compensation [Abstract]	'	'
Fair value of share-based compensation awards, granted	$20.30	$16.60
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	$49.10	'
Weighted average recognition period for unrecognized compensation expense, in years	'2 years 3 months 20 days	'

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-Based Compensation [Abstract]	'	'
Expected stock price volatility	28.00%	33.00%
Expected term, in years	'5 years 8 months 15 days	'4 years 7 months 9 days
Risk-free interest rate	1.50%	0.90%
Weighted average fair value of options granted	$35.94	$26.58

Inventories_Schedule_Of_Compon

Inventories (Schedule Of Components Of Inventories) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$23,498	$23,766
Work-in-process	16,120	14,359
Finished goods	101,516	95,302
Inventories	$141,134	$133,427

Other_Noncurrent_Assets_Schedu

Other Noncurrent Assets (Schedule Of Other Noncurrent Assets) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Noncurrent Assets [Abstract]	'	'
Investment in long-term product supply arrangements	$12,577	$13,075
Customer acquisition costs, net	20,781	21,199
Other assets	25,827	22,957
Other noncurrent assets, net	$59,185	$57,231

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Accrued expenses	$44,567	$44,274
Accrued employee compensation and related expenses	48,105	62,474
Accrued taxes	15,386	16,508
Accrued customer programs	26,461	25,663
Accrued liabilities	$134,519	$148,919

Repurchases_Of_Common_Stock_De

Repurchases Of Common Stock (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Repurchases Of Common Stock [Abstract]	'	'
Shares repurchased	576,000	687,000
Total cost of shares repurchased	$70,279,000	$63,778,000
Average cost per share	$122.04	$92.82
Shares acquired through employee surrenders	40,537	45,181
Cost of shares acquired through employee surrenders	$5,000,000	$4,100,000

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Abstract]	'	'
Effective Tax Rate	31.20%	26.20%

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income [Abstract]	'	'
Beginning balance, Unrealized gain on investments, net of tax	$108	'
Beginning balance, Unrealized loss on derivatives instruments, net of tax	-179	'
Beginning balance, Unrealized gain on cumulative translation adjustment	13,693	'
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($32) in 2014 and $42 in 2013	-54	72
Other Comprehensive (Loss) Income, Unrealized (Loss) Gain on Derivatives Arising During Period, Net of Tax	-253	4,118
Less: reclassification adjustment for gains included in net income, net of tax (expense) benefit of ($47) in 2014 and $8 in 2013	-149	-10
Current-period other comprehensive income (loss), Unrealized gain (loss) on cumulative translation adjustment	1,279	-8,447
Current-period other comprehensive income (loss), Unrealized (loss) gain on derivatives instruments, net of tax	-402	4,108
Current-period other comprehensive income (loss), Unrealized gain (loss) on cumulative translation adjustment	1,279	-8,447
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-149	'
Ending balance, Unrealized gain on investments, net of tax	54	'
Ending balance, Unrealized loss on derivatives instruments, net of tax	-581	'
Ending balance, Unrealized gain on cumulative translation adjustment	14,972	'
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance	13,622	'
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance	14,445	'
Accumulated Other Comprehensive Income, before Tax	$972	'

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$149	'
Provision for income taxes	21,150	15,930
Reclassifications out of Accumulated Other Comprehensive Income [Member]	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	196	2
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	149	10
Provision for income taxes	47	-8
Interest Rate Swaps [Member] | Reclassifications out of Accumulated Other Comprehensive Income [Member]	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	-262	-107
Foreign Currency Exchange Contracts [Member] | Reclassifications out of Accumulated Other Comprehensive Income [Member]	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$458	$109

Earnings_Per_Share_Schedule_Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Shares outstanding for basic earnings per share	51,617	54,588
Dilutive effect of share-based payment awards	721	902
Shares outstanding for diluted earnings per share	52,338	55,490

Earnings_Per_Share_Schedule_Of1

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options and Restricted Stock Units) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]	'	'
Antidilutive Securities [Line Items]	'	'
Weighted average number of shares underlying anti-dilutive options	217	441
Restricted Stock Units (RSUs) [Member]	'	'
Antidilutive Securities [Line Items]	'	'
Weighted average number of shares underlying anti-dilutive options	41	'

Segment_Reporting_Summary_Of_S

Segment Reporting (Summary Of Segment Performance) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue	$360,203	$332,106
Income (loss) from operations	70,046	61,188
Interest expense, net	-2,303	-391
Income before provision for income taxes	67,743	60,797
Provision for income taxes	21,150	15,930
Net income	46,593	44,867
Less: Net income attributable to noncontrolling interest	8	7
Net income attributable to IDEXX Laboratories, Inc. stockholders	46,585	44,860
Depreciation and amortization	13,394	13,513
Expenditures for long-lived assets	11,298	20,132
CAG Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	301,588	276,941
Income (loss) from operations	55,864	51,309
Water Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	21,421	20,666
Income (loss) from operations	8,116	8,355
LPD Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	31,351	28,039
Income (loss) from operations	6,460	4,836
Other Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	5,843	6,460
Income (loss) from operations	589	435
Unallocated Amounts [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Income (loss) from operations	($983)	($3,747)

Segment_Reporting_Summary_Of_R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue	$360,203	$332,106
CAG Diagnostics Recurring Revenue [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	258,763	239,568
IDEXX VetLab Consumables [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	84,321	75,783
VetLab Service and Accessories [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	13,093	12,053
Rapid Assay Products [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	43,059	44,083
Reference Laboratory Diagnostic And Consulting Services [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	118,290	107,649
CAG Diagnostic Capital - Instruments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	18,565	15,835
Customer Information Managment and Digital Imaging Systems [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	24,260	21,538
CAG Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	301,588	276,941
Water Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	21,421	20,666
LPD Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	31,351	28,039
Other Segment [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	$5,843	$6,460

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) (USD $)	Mar. 31, 2014		Dec. 31, 2013
Prepaid Expense and Other Assets [Abstract]	'		'
Carrying value of notes receivable	$5,200,000		'
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	173,116,000	[1]	153,109,000
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	173,116,000	[1]	153,109,000
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	2,765,000	[2]	2,847,000
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	2,765,000	[2]	2,847,000
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	3,014,000	[3]	4,044,000	[3]
Fair value of Liabilities	2,576,000	[3]	3,096,000	[3]
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Assets	3,014,000	[3]	4,044,000	[3]
Fair value of Liabilities	2,576,000	[3]	3,096,000	[3]
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Liabilities	2,765,000	[4]	2,847,000
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Liabilities	2,765,000	[4]	2,847,000
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Liabilities	1,637,000	[5]	1,821,000
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member] | Significant Other Observable Inputs (Level 2) [Member]	'		'
Prepaid Expense and Other Assets [Abstract]	'		'
Fair value of Liabilities	$1,637,000	[5]	$1,821,000
[1]	Money market funds are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of March 31, 2014 and December 31, 2013 consisted of demand deposits.
[2]	Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability.
[3]	Foreign currency exchange contracts are included within other current assets; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.
[4]	A deferred compensation plan assumed as part of a previous business combination is included within other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above.
[5]	Interest rate swaps are included within accrued liabilities.

Derivative_Instruments_And_Hed3

Derivative Instruments And Hedging (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Derivative [Line Items]	'	'
Estimated net amount of losses that are expected to be reclassified out of accumulated other comprehensive income and into earnings within the next 12 months	$600,000	'
General duration of foreign currency exchange contracts	'24 months	'
Notional Amount of Foreign Currency Exchange Contracts	179,000,000	168,300,000
Interest Rate Swap Effective On March 30, 2012 [Member]	'	'
Derivative [Line Items]	'	'
Fixed portion of interest rate associated with interest rate swap	1.36%	'
Credit Facility borrowings hedged	40,000,000	'
Interest Rate Swap Effective On March 28, 2013 [Member]	'	'
Derivative [Line Items]	'	'
Fixed portion of interest rate associated with interest rate swap	1.64%	'
Credit Facility borrowings hedged	$40,000,000	'

Derivative_Instruments_And_Hed4

Derivative Instruments And Hedging (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of assets	$3,014	$4,044
Total derivative instruments, fair value of liabilities	4,213	4,917
Derivative Asset, Fair Value, Amount Not Offset Against Collateral	2,561	2,965
Derivative Asset	453	1,079
Derivative Liability	1,652	1,952
Derivatives Designated As Hedging Instruments [Member] | Accrued Expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of liabilities	2,571	3,096
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of assets	3,003	4,044
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Assets Net [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of assets	11	'
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of liabilities	5	'
Interest Rate Swaps [Member] | Derivatives Designated As Hedging Instruments [Member] | Accrued Expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total derivative instruments, fair value of liabilities	$1,637	$1,821

Derivative_Instruments_And_Hed5

Derivative Instruments And Hedging (Gain (Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) (Cash Flow Hedges [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Foreign Currency Exchange Contracts [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	($517)	$4,061
Interest Rate Swaps [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	115	47
Derivatives Designated As Hedging Instruments [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	($402)	$4,108